Exelon Sees 12% Growth in Data-Center Demand Amid Rising Electricity Consumption

Axsome Therapeutics (AXSM) reported a Q3 loss of 94 cents per share, wider than the Zacks Consensus Estimate of a loss of 82 cents. Total revenues surged 63% YoY to $171 million, beating the Zacks Consensus Estimate of $164 million. The year-over-year increase in revenues can be attributed to strong sales of Auvelity. Net product revenues were $169.8 million, reflecting an increase of 63.7% YoY.